

IAP7 Rec'd PCT/PTO 08 JUN 2006

PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of

SASAKI, S. et al.

Serial No. 10/511,341

Filed: October 15, 2004

For: ENDOCRINE CELL LINES AND METHOD OF USING THE  
SAME

Atty. Ref.: 4093-8

Group: Unassigned

Examiner: Unassigned

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

June 8, 2006

Sir:

**INFORMATION DISCLOSURE STATEMENT**

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

RECEIVED

26 JUN 2006

Legal Staff  
International Division  
1082452

The following are submitted in the above-identified application in compliance with  
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

SASAKI, S. et al.  
Serial No. 10/511,341

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_



B. J. Sadoff  
Reg. No. 36,663

901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE  
CITATION**

PRIORITY DOCKET NO.

SERIAL NO.

4093-8

10/511,341

APPLICANT

SASAKI, S. et al.

(Use several sheets if necessary)

FILING DATE

GROUP

October 15, 2004

Unassigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,194,176	02/2001	Newgard et al			

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
JP 2001-245666	09/2001	Japan				
WO 01/14883	03/2001	WIPO				
WO 96/34112	10/1996	WIPO				
WO 00/28083	05/2000	WIPO				
WO 92/02639	02/1992	WIPO				
WO 99/50657	10/1999	WIPO				

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Yoshino et al, No To Shinkei (Brain and Nerve), 1995, 47(12):1149-1157
	Takahashi et al, Exp. Anim., 1999, 48(4):255-261
	Teitz et al, DNA and Cell Biology, 1994, 13(7):705-710
	Thirumoorthy et al, J. Med. Chem., 2001, 44, 4114-4124
	Sawzdargo et al, Biochemical and Biophysical Research Communications, 1997, Vol. 239, pp 543-547
	Bonini et al, Biochemical and Biophysical Research Communications, 1997, 234, 190-193
	Harrison et al, FEBS Lett., 1993, Vol. 318, No. 1, pp 17-22
	Parker et al, Oncogene, 2000, Vol. 19, pp 700-709
	Ozaki et al, Nature Cell Biology, 2000, Vol. 2, pp 805-811
	Rasmussen et al, Endocrinology, 1990, Vol. 126, No. 1, pp 235-240
	Fitzpatrick et al, Endocrinology, 1999, Vol. 140, No. 9, pp 3928-3937
	Mellon et al, Neuron, 1990, Vol. 5, pp 1-10
	Radovick et al, Proc. Natl. Acad. Sci., 1991, Vol. 88, pp 3402-3406
	Efrat et al, Proc. Natl. Acad. Sci., 1988, Vol. 85, pp 9037-9041
	Hamaguchi et al, Diabetes, 1991, Vol. 40, pp 842-849
	Miyazaki et al, Endocrinology, 1990, Vol. 127, No. 1, pp 126-132
	Powers et al, Diabetes, 1990, Vol. 39, pp 406-414
	Hamaguchi et al, Diabetes, 1990, Vol. 39, pp 415-425
	Pettengill et al, Carcinogenesis, 1994, Vol. 15, No. 1, pp 61-65
	Hemmi et al, Cell, 1994, Vol. 76, pp 803-810

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

